Professor Andrew Pearson – Cancer Research UK Professor of Paediatric Oncology
Professor Pearson’s research focuses on improving the outcome of children with poor prognosis cancers (neuroblastoma, glioma, sarcoma and leukaemia) by introducing into the clinic new anti-cancer drugs, underpinned by strong pre-clinical and clinical research. He has a strong interest in neuroblastoma and the development of novel therapeutics for high risk neuroblastoma.
Professor John Anderson – Professor of Experimental Paediatric Oncology at the UCL Institute of Child Health
Professor Anderson was appointed as a Clinical Lecturer in paediatric oncology at UCL Institute of Child Health in 1998 after completing his PhD, which he undertook as a clinical research fellow at the Institute of Cancer Research (1995-1998). His initial 4 year appointment (1998-2002) at ICH was funded by a donation to ICH from the Great Ormond Street Hospital Special Trustees. In 2001 he was awarded a Cancer Research UK (then the Cancer Research Campaign) ClinicianScientist Fellowship (2002-2007). Since 2007, he holds a HEFCE Senior Clinical Fellowship.
Dr. Mark Gaze – Consultant Clinical Oncologist at Great Ormond Street Hospital
Mark Gaze has been a consultant clinical oncologist at University College London Hospitals and Great Ormond Street Hospital for Children since 1993. His particular areas of expertise include the management of cancer in children and young people with radiotherapy, and the use of radionuclide therapy in adults and children.
Dr. Hung Chi Tran – Assistant Professor of Clinical Paediatrics at the USC Keck School of Medicine
Dr. Hung Chi Tran MD is a male Paediatrician, has 6 years of experience and practices in Paediatrics and Paediatric Haematology-Oncology.
Professor Rupert Handgretinger – Professor of Paediatrics and Managing Medical Director of the Department of Paediatrics at the University of Tübingen Hospital
Rupert Handgretinger is a professor of Paediatrics and chairman of the Department of General Paediatrics and Haematology/Oncology at the Children’s Hospital, University of Tubingen. His primary research has focused on cellular immunotherapeutic approaches to the treatment of children with various cancers.
Dr. Shakeel Modak – Paediatric Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC)
Dr Modak is a paediatric oncologist who specializes in the treatment of children and young adults with neuroblastoma and other solid tumours, such as desmoplastic small round cell tumours. They are challenging cancers to treat. By caring for patients and conducting research, he hopes to be able make an impact and improve the lives of people diagnosed with these diseases.
Dr Louis Chesler– Reader in Paediatric Solid Tumour Biology and Therapeutics at the Institute of Cancer Research (ICR)
The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCN is very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.
Dr. Daniel Morgenstern – Consultant and Honorary Senior Lecturer in Paediatric Oncology at Great Ormond Street Hospital
Dr Daniel Morgenstern is a Consultant Paediatric Oncologist and Honorary Senior Lecturer at Great Ormond Street Hospital (GOSH) and University College London.
Dr Morgenstern has a particular interest in neuroblastoma, one of the most common types of solid tumour affecting children, and has experience of both the clinical management of patients and scientific research into this disease.
Dr. Araz Marachalian – Assistant Medical Director at New Approaches to Neuroblastoma Therapy
Dr. Brian Kushner – Paediatric Oncologist at Memorial Sloan Kettering Cancer Center
Dr Kushner is a paediatric oncologist whose speciality is neuroblastoma. We’ve made significant progress in improving the outlook for many children newly diagnosed with this challenging disease, and we are now able to achieve the best cure rates. For those whose disease returns, we are devising new approaches that are showing encouraging results.
Dr. Nick Bown – Head of Cytogenetics Laboratory at Newcastle University
Dr. Kate Wheeler is currently a Consultant in Paediatric Oncology at Oxford University Hospitals NHS Trust and Honorary Senior Clinical Lecturer at the University of Oxford. She is the current chair of the UK neuroblastoma group (SIOPEN), a sub-group of the UK National Cancer Research Institute Clinical Study Group for Childhood Cancer and Leukaemia.
Dr. Juliet Gray – Consultant Paediatric Oncologist, University Hospital Southampton
Dr. Gray’s main research interest is in the development of new immunotherapies to treat neuroblastoma. She is currently working on using monoclonal antibodies to target cancer cells. She is a member of the SIOP European Neuroblastoma research Network and UK Children’s Cancer and Leukaemia Group (CCLG) New Agents Group.
Dr. Andras Heczey is based at Texas Children’s Hospital, Houston and is an Assistant Professor in the department of paediatric Haematology-oncology at the University of Baylor. He has studied and published the first adoptive immunotherapy approach to neuroblastoma treatment utilizing genetically modified Natural Killer T cells. He is working on moving this approach from bench-to-bedside in a form of a Phase 1/2a clinical trial.
Professor Frank Berthold is a paediatric oncologist in Cologne, Germany. He is the deputy chair of the Society for Paediatric Oncology and Haematology and an advisor on the Cancer Therapy Evaluation Programme in the USA.
Scott Kennedy – Co-founder and Executive Director of Solving Kids’ Cancer
Scott co-founded SKC in 2007 as a tribute to his son, Hazen Kennedy, who was diagnosed with neuroblastoma at age 3. Hazen was Scott’s inspiration for creating Solving Kids’ Cancer in part because Hazen wanted to become a scientist when he grew up in order to help people by creating new medicines. As Executive Director, Scott Kennedy is involved in all aspects of SKC, from managing operational staff and fundraising to policy development and fiscal management. He is integrally involved in the identification, funding, and management of the organization’s scientific programs.
Donna Ludwinski – Co-director of Research Programs and Partnerships at Solving Kids’ Cancer
Admiration for the SKC mission and method noted while her son Erik battled neuroblastoma led to a productive collaboration after his death in 2010. Donna is a voracious consumer of medical literature and has has spent most of her waking hours the past 8 years reading and reporting on clinical and pre-clinical papers and abstracts on paediatric solid tumours. She attends major oncology conferences and keeps abreast of promising research leads. A lay member of the TDI, she assists in identifying, analysing, and cultivating promising therapeutic leads to bring novel therapies into the clinic quickly. Passionate about providing resources and advocating for families dealing with childhood cancer, she also serves as a liaison with other foundations with similar goals and focus.
Patricia Tallungan – Founder and President of The Children’s Neuroblastoma Cancer Foundation (CNCF)